Mechanisms underlying the chemopreventive effect of difluoromethylornithine (DFMO) on the development of mammary cancer were investigated utilizing the whey acidic protein promoter-T antigen transgenic mouse model of breast cancer progression. Mice were exposed to four different doses of DFMO in the diet (3.5, 4.9, 7.0 and 10 g/kg diet). Tumor latency was increased in a dosedependent manner. DFMO at the highest dose significantly delayed tumor onset (131 days as compared to 109 days in control unexposed mice, P ¼ 0.018). Analyses of preneoplastic mammary tissue collected 1 month after DFMO treatment demonstrated that DFMO (10 g/kg diet) significantly increased the ratio of apoptotic to proliferative indices (P ¼ 0.013) and significantly reduced the percentage of cells demonstrating nuclear localized cyclin D1 (P ¼ 0.013). Nuclear localizations of p27, p21 and Stat5a were not affected. Inhibitory effects of DFMO on cell growth and survival were lost as the cells progressed to cancer. In conclusion, the chemopreventive effects of DFMO on mammary cancer progression were mediated by changes in both apoptosis and cell proliferation in preneoplastic cells. Alterations in cyclin D1 activity in preneoplastic cells could represent an early biomarker of chemopreventive action and are consistent with a mechanistic role for cyclin D1 in progression of mammary cancer.
Mechanisms underlying the chemopreventive effect of difluoromethylornithine (DFMO) on the development of mammary cancer were investigated utilizing the whey acidic protein promoter-T antigen transgenic mouse model of breast cancer progression. Mice were exposed to four different doses of DFMO in the diet (3.5, 4.9, 7.0 and 10 g/kg diet). Tumor latency was increased in a dosedependent manner. DFMO at the highest dose significantly delayed tumor onset (131 days as compared to 109 days in control unexposed mice, P ¼ 0.018). Analyses of preneoplastic mammary tissue collected 1 month after DFMO treatment demonstrated that DFMO (10 g/kg diet) significantly increased the ratio of apoptotic to proliferative indices (P ¼ 0.013) and significantly reduced the percentage of cells demonstrating nuclear localized cyclin D1 (P ¼ 0.013). Nuclear localizations of p27, p21 and Stat5a were not affected. Inhibitory effects of DFMO on cell growth and survival were lost as the cells progressed to cancer. In conclusion, the chemopreventive effects of DFMO on mammary cancer progression were mediated by changes in both apoptosis and cell proliferation in preneoplastic cells. Alterations in cyclin D1 activity in preneoplastic cells could represent an early biomarker of chemopreventive action and are consistent with a mechanistic role for cyclin D1 in progression of mammary cancer. Oncogene (2003 Oncogene ( ) 22, 2568 Oncogene ( -2572 Oncogene ( . doi:10.1038 Keywords: DFMO; cell proliferation; apoptosis; cyclin D1; transgenic mouse model; mammary cancer progression Difluoromethylornithine (DFMO) is a synthetic inhibitor of ornithine decarboxylase (ODC), the key enzyme in the synthesis of polyamines (Pegg et al., 1987) and is effective in preventing colon and skin oncogenesis (Kingsnorth et al., 1983; Reddy et al., 1990) . DFMO delays rat mammary tumor progression (Thompson and Ronan, 1986; Ratko et al., 1990) . Since almost all rat mammary tumors are estrogen dependent, these tumors generally respond to agents that interrupt estrogensignaling pathways (Nandi et al., 1995) . However, estrogen is not the only factor that affects human breast cancer development (Kelloff et al., 1998) . Unlike rat mammary tumors and like a significant portion of human breast cancer, mouse mammary tumors are less estrogen dependent. In mice, ovariectomy neither blocks tumor development nor causes tumor regression (Nandi et al., 1995; Russo and Russo, 1996) . Therefore, mouse mammary tumor models overcome the shortcoming of rat mammary tumor models in screening for agents that prevent hormone-independent breast cancer. To date, only a few mouse mammary tumor models have been utilized to identify mechanisms of chemoprevention (Green et al., 2001; Hursting et al., 2001) .
The whey acidic protein promoter-T antigen (WAPTAg) transgenic mouse model is used to investigate effects on both early and late stages of mammary tumor progression (Tzeng et al., 1993; Li et al., 1996; Furth et al., 1999; Li et al., 2000; Ren et al., 2002) . In this model, the Simian Virus 40 large TAg is expressed in mammary epithelial cells under control of the WAP. Expression begins after puberty specifically in ductal mammary epithelial cells. During pregnancy TAg also is expressed in alveolar cells. By 7 months of age, 100% of female mice develop mammary adenocarcinomas. The tumors exhibit histological features similar to human breast cancers (Furth et al., 1999; Li et al., 2000) and bear some analogy to the subset of human breast cancers that have p53 mutations and one or more of the relatively common alterations of elements of the Rb pathway including amplification and/or over expression of cyclin D1, decreased expression of p16, or other genetic changes (Ioachim et al., 2000) as SV40 TAg inactivates the function of both p53 and Rb (Furth, 1998) . Previous studies employed the model to investigate the impact of Bcl-2 and Maspin overexpression and loss of Stat5a at specific stages of mammary cancer progression (Furth et al., 1999; Zhang et al., 2000; Ren et al., 2002) .
First, nontransgenic female mice were fed a diet containing different concentrations of DFMO (0, 3.5, 4.9, 7.0 and 10 g/kg diet) to test for systemic toxicity. There was no systemic toxicity after 6 weeks of treatment. To examine the effects of DFMO treatment on mammary cancer progression, transgenic female mice were exposed to DFMO after initiation of carcinogenesis by TAg expression. To exclude the possibility that DFMO influenced TAg expression, steady-state levels of TAg were measured by immunohistochemistry and Western blot analysis and compared to mice with or without DFMO treatment (10 g/kg diet) for 30 days. DFMO treatment did not downregulate TAg expression (Figure 1a ). Tumor latency was increased in a dose-dependent manner (Figure 2 ). DFMO at the highest dose in this study (10 g/kg diet) significantly delayed tumor onset from a mean of 109 days in control mice to a mean of 131 days in DFMOtreated mice (Student's t-test, P ¼ 0.018). There was no significant effect on tumor growth rate or tumor histology. The average doubling time of the tumors (n ¼ 12) from the DFMO-treated mice was 7.3 days versus 6.8 days in the control mice (n ¼ 15).
The observation that DFMO significantly reduced the average time to tumor onset, but did not affect growth of the established tumors, suggested that DFMO inhibited the growth of preneoplastic mammary epithelial cells. To test this hypothesis, the effect of DFMO on growth of preneoplastic mammary epithelial cells in mice with and without exposure to DFMO (10 g/kg diet) for 1 month was analysed by determining the percentages of apoptotic mammary epithelial cells (apoptotic index (AI)) ( Figure 1b ) and proliferating mammary epithelial cells (proliferative index (PI)) ( Figure 1c ) for individual mice and calculating the AI/PI ratios ( Figure 3) . The AI/PI ratio was increased significantly in mammary epithelial cells from DFMO-treated mice (0.05870.001 as compared to 0.01370.003 in control mice; ANOVA, P ¼ 0.013) indicating that DFMO exposure inhibited the growth of preneoplastic mammary epithelial cells. Although DFMO was initially hypothesized to affect primarily cell proliferation (Peralta Soler et al., 1998) , both the present study and a previous study in a transgenic mouse model of skin cancer demonstrated significant apoptosis following treatment with this agent (Arbeit et al., 1999) .
To investigate possible mechanisms associated with the inhibition of cell growth by DFMO and to identify early biomarkers for chemopreventive activity, cellular localizations of cyclin D1, p21, p27 and Stat5a were assessed by immunohistochemistry. The percentage of cells demonstrating cyclin D1 nuclear localization was significantly reduced by DFMO treatment (5.771.4% as compared to 10.570.4%, ANOVA, P ¼ 0.013) (Figure 4a ). Cellular localizations of p27, Stat5a and p21 were not affected by DFMO treatment (Figure 4b-d) . Cyclin D1 accumulates in the cell nucleus during the G 1 phase of the cell cycle and is required for cell cycle progression (Baldin et al., 1993; Diehl et al., 1998; Alt et al., 2002) . Reductions in cyclin D1 activity has been associated with induction of apoptosis and growth arrest or growth inhibition in cancer cells following exposure to several different chemopreventive or antitumor agents including flavopiridol (Zhai et al., 2002) , apigenin, a dietary flavonoid, (Gupta et al., 2002) , lipoxygenase inhibitors (Pidgeon et al., 2002; Seufferlein et al., 2002) , all-trans-retinyl palmitate (Masuda et al., 2002) and resveratrol (Joe et al., 2002) . Increased levels of cyclin D1 expression are found in the mammary gland tissue of the WAP-TAg mice as the lesions Figure 1 TAg expression, apoptosis and proliferation in preneoplastic mammary epithelial cells. Transgenic female mice were identified using a simplified PCR procedure (Ren et al., 2000) and mated at the age of 2 months. DFMO administration (10 g/kg diet) was begun at the time of parturition at an age less than 100 days. Mammary tissues were collected at 30 days involution. Tissues were fixed in 10% neutral buffered formalin at 41C overnight for immunohistochemical analysis of TAg expression (a), apoptosis (b) and cell proliferation (c) or snap frozen for Western blot analysis of TAg expression (A) using methods described previously (Li et al., 1996 . Apoptotic cells were identified using TDT-mediated dUTP nick-end labeling. BrdU (20 ml/g body weight; Amersham Pharmacia Biotech Inc. Piscataway, NJ, USA) was administered 4 h prior to euthanization to identify proliferating cells. Arrows indicate mammary epithelial cells exhibiting nuclear staining for TAg (a), apoptotic mammary epithelial cells (b), and BrdU-labeled mammary epithelial cells (c). Western blot (a) demonstrates TAg expression levels in mammary tissue from control (lanes 1-4) and DFMO-treated (lanes 5-8) mice. Bars, 20 mm DFMO delays mammary cancer progression M Li et al progress to cancer . The reduction in cyclin D1 activity found at this early time point may represent a significant biomarker of chemopreventive action. Very few cells (less than 0.1%) were stained for p21 (Figure 4c ) regardless of treatment, consistent with the absence of functional p53 in this mouse model. Stat5a is activated and nuclear localized independent of pregnancy in the WAP-TAg mouse model (Figure 4d ) and acts as a survival factor (Ren et al., 2002) .
DFMO treatment did not affect weight gain or cause gross toxicity in the mice; however, it did prevent successful pregnancy at the three highest doses.
Subgroups of five mice from each of the different dosage groups were mated after DFMO treatment. All mice from the control group and DFMO (3.5 g/kg diet)-treated group became pregnant within 20 days. None of the mice treated with DFMO at concentrations of 4.9 g/ kg in the diet or higher became pregnant. This effect on pregnancy was reversible. Mice taken off DFMO after treatment for at least 1 month were able to become pregnant within 20 days. DFMO exposure did not prevent estrus-diestrus as measured by the vaginal smear technique (Cooper et al., 1993) and did not alter ovarian histology. It is likely that the inhibitory effect of DFMO on pregnancy is secondary to effects on the uterus consistent with previous reports from the rat (Fozard et al., 1980; Reddy and Rukmini, 1981) .
A similar preventive effect of DFMO on mammary tumorigenesis was observed in the C3(1)/SV40 mouse model of mammary cancer (Green et al., 2001) . In contrast to the WAP promoter that directs initial TAg expression to ductal mammary epithelial cells following puberty and alveolar cells during pregnancy, the C3(1) promoter directs initial TAg expression to terminal end buds, terminal ductal lobular units and ductal mammary epithelial cells (Yoshidome et al., 2000) . In the C3(1)/ SV40 mouse model DFMO treatment (8 g/kg diet) reduced the incidence of palpable tumor by approximately 20% and tumor multiplicity by approximately 70%. In the WAP-TAg mice, a higher dose of DFMO (10 g/kg diet) reduced the tumor incidence by approximately 30% (Figure 2b ). Tumor multiplicity was not reduced significantly (1.3 tumors/mouse in DFMOtreated mice as compared to 1.8 tumors/mouse in untreated control mice). It is possible that tumor multiplicity was not reduced significantly in the WAPTAg mice, because the average number of tumors/ mouse in the control group (1.8) was much less than that reported in the C3(1)/SV40-untreated control group (4.5). In the C3(1)/SV40 study, no differences in apoptosis or proliferation were found in preinvasive lesions, but the DFMO dose was less (8 g/kg diet as Figure 3 DFMO treatment increased the ratio of apoptotic to proliferative cells in preneoplastic mammary tissue. There was a statistically significant increase in the AI/PI ratio in the mammary glands of DFMO-treated (10 g/kg diet) (0.05870.001) as compared to control (0.01370.003) mice (ANOVA, P ¼ 0.013). The AI was determined by calculating the percentage of apoptotic cells within a total population of 500 preneoplastic mammary epithelial cells in DFMO-treated (1.8%70.6, n ¼ 5) and control 0.6%70.2, n ¼ 5) glands. The PI was determined by calculating the percentage of BrdU-labeled cells within a population of 500 preneoplastic mammary epithelial cells in n ¼ 5) and control (51.8712.7, n ¼ 5) glands and the AI/PI ratio was calculated for individual mice. Standard errors of the mean are indicated compared to 10 g/kg diet in the WAP-TAg mice), bromodeoxyuridine (BrdU) labeling was carried out for 1 h in the C3(1)/SV40 mice as compared to 4 h in the WAP-TAg mice, the duration of TAg exposure was not the same (the C3(1) promoter initiates TAg expression before puberty, while the WAP promoter initiates TAg expression only after puberty), terminal end buds and terminal ductal lobular units are targeted by the C3(1) promoter, while the WAP promoter does not direct TAg expression to these cells, and the duration of DFMO exposure was slightly different (5 weeks in the C3(1)/ SV40 mice and 4 weeks in the WAP-TAg mice).
In summary, DFMO (10 g/kg diet) significantly increased tumor latency by altering rates of cell proliferation and apoptosis in preneoplastic mammary epithelial cells. These alterations were associated with a reduction in the percentage of cells demonstrating nuclear localized cyclin D1. Changes in cyclin D1 activity could be an early biomarker of chemopreventive action and are consistent with a mechanistic role for cyclin D1 in mammary cancer progression.
